NEW YORK, Feb. 17, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Catalyst Pharmaceuticals, Inc. ("Catalyst" or "the Company") (NASDAQ: CPRX). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at email@example.com or 212-697-6484.
This investigation concerns whether Catalyst and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
On February 17, 2016, pre-market, Catalyst revealed that it has received a "Refusal To File" letter from the U.S. Food and Drug Administration (FDA) in relation to Firdapse (amifampridine phosphate), its New Drug Application. The "Refusal to File" letter explains that following December 2015 submission and the initial review, the FDA has found that the application was not adequately complete and needs additional supporting information. The letter does not note the acceptability of the clinical data and does not discuss the efficacy or safety of Firdapse.
Following this news, Catalyst stock has fallen as much as $0.92 per share, or roughly 50%, to just $0.93 per share during early intraday trading on February 17, 2016.
If you are aware of any facts relating to this investigation, or purchased shares of Catalyst, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!cprx/cuvwc. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC